KR20120050477A - 유동성 마이크로과립체 - Google Patents

유동성 마이크로과립체 Download PDF

Info

Publication number
KR20120050477A
KR20120050477A KR1020127006333A KR20127006333A KR20120050477A KR 20120050477 A KR20120050477 A KR 20120050477A KR 1020127006333 A KR1020127006333 A KR 1020127006333A KR 20127006333 A KR20127006333 A KR 20127006333A KR 20120050477 A KR20120050477 A KR 20120050477A
Authority
KR
South Korea
Prior art keywords
granules
flowable
active ingredient
solid core
cellulose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127006333A
Other languages
English (en)
Korean (ko)
Inventor
크리스토프 르봉
파스칼 서플리에
Original Assignee
데브레게아 에 아쏘시에 파르마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데브레게아 에 아쏘시에 파르마 filed Critical 데브레게아 에 아쏘시에 파르마
Publication of KR20120050477A publication Critical patent/KR20120050477A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Manufacture Of Metal Powder And Suspensions Thereof (AREA)
  • Glanulating (AREA)
KR1020127006333A 2009-08-12 2010-08-11 유동성 마이크로과립체 Ceased KR20120050477A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0955641A FR2949061B1 (fr) 2009-08-12 2009-08-12 Microgranules flottants
FR0955641 2009-08-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030037A Division KR20170119743A (ko) 2009-08-12 2010-08-11 유동성 마이크로과립체

Publications (1)

Publication Number Publication Date
KR20120050477A true KR20120050477A (ko) 2012-05-18

Family

ID=42115979

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020127006333A Ceased KR20120050477A (ko) 2009-08-12 2010-08-11 유동성 마이크로과립체
KR1020177030037A Ceased KR20170119743A (ko) 2009-08-12 2010-08-11 유동성 마이크로과립체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020177030037A Ceased KR20170119743A (ko) 2009-08-12 2010-08-11 유동성 마이크로과립체

Country Status (34)

Country Link
US (1) US8916202B2 (enExample)
EP (1) EP2464333B1 (enExample)
JP (1) JP6068142B2 (enExample)
KR (2) KR20120050477A (enExample)
CN (1) CN102548541B (enExample)
AR (1) AR077864A1 (enExample)
AU (1) AU2010283608B9 (enExample)
BR (1) BR112012003289B1 (enExample)
CA (1) CA2771053C (enExample)
CL (1) CL2012000376A1 (enExample)
CY (1) CY1118119T1 (enExample)
DK (1) DK2464333T3 (enExample)
EA (1) EA023532B1 (enExample)
ES (1) ES2588430T3 (enExample)
FR (1) FR2949061B1 (enExample)
HR (1) HRP20161149T1 (enExample)
HU (1) HUE030027T2 (enExample)
IL (1) IL218072A (enExample)
IN (1) IN2012DN01864A (enExample)
LT (1) LT2464333T (enExample)
MA (1) MA33523B1 (enExample)
MX (1) MX2012001878A (enExample)
NZ (1) NZ598468A (enExample)
PE (1) PE20120805A1 (enExample)
PL (1) PL2464333T3 (enExample)
PT (1) PT2464333T (enExample)
SG (1) SG180305A1 (enExample)
SI (1) SI2464333T1 (enExample)
SM (1) SMT201600347B (enExample)
TN (1) TN2012000068A1 (enExample)
TW (1) TWI478731B (enExample)
UA (1) UA107361C2 (enExample)
WO (1) WO2011018582A2 (enExample)
ZA (1) ZA201201711B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9321956B2 (en) 2012-11-28 2016-04-26 Halliburton Energy Services, Inc. Methods for hindering the settling of particulates in a subterranean formation
WO2015102629A1 (en) 2014-01-02 2015-07-09 Halliburton Energy Services, Inc. Generating and maintaining conductivity of microfractures in tight formations by generating gas and heat
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
CA2989297A1 (en) 2015-07-24 2017-02-02 Halliburton Energy Services, Inc. Microbubbles for heat and/or gas generation in subterranean formations
CA2986545C (en) 2015-07-24 2019-09-03 Halliburton Energy Services, Inc. Microbubbles for treatment chemical delivery in subterranean formations
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
IL275312B2 (en) 2017-12-18 2024-09-01 Tris Pharma Inc Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system
JP2021506984A (ja) * 2017-12-18 2021-02-22 トリス・フアルマ・インコーポレーテツド トリガーパルス薬物放出を有する胃内滞留型ｒａｆｔ形成システムを含む放出調節薬物粉末組成物
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
AU2020231916B2 (en) 2019-03-01 2025-08-28 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
NL2024652B1 (en) * 2020-01-10 2021-09-07 Stabican B V Process for preparing cannabinoid-containing particles
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5276418A (en) * 1975-12-19 1977-06-27 Microbial Chem Res Found Method of preparing foamable micro-capsule preparations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
US4424235A (en) 1981-09-14 1984-01-03 Hoffmann-La Roche Inc. Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor
JPS62195323A (ja) * 1986-02-24 1987-08-28 Eisai Co Ltd 胃内滞留型粒子
IT1217783B (it) 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5824339A (en) 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
US6214386B1 (en) * 1995-11-22 2001-04-10 Recordati, S.A. Prompt-release oral pharmaceutical compositions for extemporaneous suspensions
US5846971A (en) 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US6649186B1 (en) 1996-09-20 2003-11-18 Ethypharm Effervescent granules and methods for their preparation
FR2762213B1 (fr) * 1997-04-18 1999-05-14 Synthelabo Composition pharmaceutique a retention gastrique
SE9702533D0 (sv) * 1997-07-01 1997-07-01 Astra Ab New oral formulation
JP3447042B2 (ja) 1997-07-23 2003-09-16 フロイント産業株式会社 単一物質球形粒の製造方法
US20050244497A1 (en) * 1997-11-05 2005-11-03 Wockhardt Limited Delayed delivery system for acid-sensitive drugs
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
FR2784583B1 (fr) * 1998-10-16 2002-01-25 Synthelabo Composition pharmaceutique a residence gastrique et a liberation controlee
JP4374441B2 (ja) 1998-12-23 2009-12-02 ジェイピーアイ コマーシャル，リミティド ライアビリティ カンパニー 睡眠発作治療のための、ガンマ−ヒドロキシ酪酸塩の微生物的に安全で安定な液剤
FR2797185B1 (fr) 1999-08-06 2001-10-26 Galenix Dev Composition pharmaceutique flottante comprenant une phase active et une phase non active
FR2823668B1 (fr) 2001-04-20 2004-02-27 Ethypharm Lab Prod Ethiques Comprimes effervescents orodispersibles
US7141250B2 (en) 2001-08-06 2006-11-28 Euro-Celtique S.A. Pharmaceutical formulation containing bittering agent
KR20040060917A (ko) 2001-08-06 2004-07-06 유로-셀티크 소시에떼 아노뉨 오피오이드 남용을 방지하기 위한 조성물 및 방법
US20030059397A1 (en) 2001-09-17 2003-03-27 Lyn Hughes Dosage forms
FR2829932B1 (fr) 2001-09-21 2006-11-24 Ellipse Pharmaceuticals Procede de fabrication d'un produit pharmaceutique administrable par voie orale avec des agents detrompeurs et produit obtenu
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
CN1688292A (zh) 2002-09-04 2005-10-26 兰贝克赛实验室有限公司 掩味剂型及其制造方法
EP2422773A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
MXPA06009991A (es) 2004-03-03 2007-04-10 Teva Pharma Una composicion farmaceutica estable que comprende un farmaco labil acido.
TW200533391A (en) * 2004-03-25 2005-10-16 Sun Pharmaceutical Ind Ltd Gastric retention drug delivery system
US8193211B2 (en) 2004-09-30 2012-06-05 Supernus Pharmaceuticals, Inc. Controlled release compositions of gamma-hydroxybutyrate
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
PT1931315E (pt) * 2005-08-24 2014-01-03 Endo Pharmaceuticals Inc Formulações de libertação sustentada de nalbufina
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
US9125833B2 (en) 2005-11-02 2015-09-08 Relmada Therapeutics, Inc. Multimodal abuse resistant and extended release opioid formulations
WO2007075980A2 (en) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
ZA200807571B (en) 2006-03-01 2009-08-26 Ethypharm Sa Crush-resistant tablets intended to prevent accidental misuse and unlawful diversion
EP2192892A2 (en) * 2007-07-27 2010-06-09 Depomed, Inc. Pulsatile gastric retentive dosage forms
EP2240022B1 (en) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Bilayered tablets comprising oxycodone and promethazine
FR2938431B1 (fr) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments

Also Published As

Publication number Publication date
PE20120805A1 (es) 2012-07-25
HRP20161149T1 (hr) 2016-11-18
EP2464333A2 (fr) 2012-06-20
ZA201201711B (en) 2012-11-28
EA023532B1 (ru) 2016-06-30
CL2012000376A1 (es) 2013-01-04
IL218072A0 (en) 2012-04-30
BR112012003289A2 (pt) 2020-08-11
CN102548541A (zh) 2012-07-04
TWI478731B (zh) 2015-04-01
JP6068142B2 (ja) 2017-01-25
PL2464333T3 (pl) 2016-12-30
TN2012000068A1 (fr) 2013-09-19
CA2771053C (fr) 2017-05-02
DK2464333T3 (en) 2016-10-03
PT2464333T (pt) 2016-10-03
CA2771053A1 (fr) 2011-02-17
FR2949061A1 (fr) 2011-02-18
FR2949061B1 (fr) 2013-04-19
EP2464333B1 (fr) 2016-06-29
HUE030027T2 (en) 2017-04-28
HK1172824A1 (en) 2013-05-03
NZ598468A (en) 2015-05-29
SMT201600347B (it) 2016-11-10
AU2010283608B2 (en) 2015-07-30
UA107361C2 (en) 2014-12-25
LT2464333T (lt) 2016-09-12
IN2012DN01864A (enExample) 2015-08-21
SI2464333T1 (sl) 2016-10-28
JP2013501762A (ja) 2013-01-17
AR077864A1 (es) 2011-09-28
EA201200269A1 (ru) 2012-11-30
SG180305A1 (en) 2012-06-28
CN102548541B (zh) 2015-03-11
ES2588430T3 (es) 2016-11-02
CY1118119T1 (el) 2017-06-28
TW201127419A (en) 2011-08-16
WO2011018582A2 (fr) 2011-02-17
AU2010283608B9 (en) 2015-08-27
US20120207843A1 (en) 2012-08-16
IL218072A (en) 2016-08-31
BR112012003289B1 (pt) 2021-07-13
AU2010283608A1 (en) 2012-03-29
WO2011018582A3 (fr) 2011-05-19
KR20170119743A (ko) 2017-10-27
MA33523B1 (fr) 2012-08-01
MX2012001878A (es) 2012-06-01
US8916202B2 (en) 2014-12-23

Similar Documents

Publication Publication Date Title
KR20120050477A (ko) 유동성 마이크로과립체
AU773555B2 (en) Taste masked pharmaceutical liquid formulations
KR101563390B1 (ko) 감마-하이드록시부티르산을 주성분으로 하는 신규 조성물
FI77573B (fi) Ny konsistens.
PL175569B1 (pl) Środki farmaceutyczne o szybkim uwalnianiu substancji czynnej i wysokiej biodostępności, o smaku maskowanym i sposób wytwarzania środków farmaceutycznych o szybkim uwalnianiu substancji czynnej i wysokiej biodostępności, o smaku maskowanym.
JP2003517470A (ja) 薬学的組成物における活性成分の改善された送達のための固体キャリア
KR20130117761A (ko) 간단한 투약을 위한 인산염 결합제 조성물
HK1172824B (en) Floating microgranules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120309

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150710

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160705

Patent event code: PE09021S01D

AMND Amendment
AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170730

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170131

Comment text: Final Notice of Reason for Refusal

Patent event code: PE06011S02I

Patent event date: 20160705

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170730

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20170321

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20160829

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20120809

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20170919

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170829

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20170730

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20170321

Comment text: Final Notice of Reason for Refusal

Patent event code: PX06013S02I

Patent event date: 20170131

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20160829

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20160705

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20120809

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171018